We are live on ! Find out more
CG

Column Group Portfolio holdings

AUM $88.1M
1-Year Est. Return 148.03%
This Fund
S&P 500
This Quarter Est. Return
-13.83%
1 Year Est. Return
+148.03%
3 Year Est. Return
+95.12%
5 Year Est. Return
+23.89%
10 Year Est. Return
–
AUM
$55.7M
AUM Growth
-$13.8M
Cap. Flow
-$2.19M
Cap. Flow %
-3.94%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$2.15M
2
SGMT icon
Sagimet Biosciences
SGMT
+$47.6K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ORIC icon
1
Oric Pharmaceuticals
ORIC
$1.44B
$28.6M 51.26%
3,540,777
– –
TNYA icon
2
Tenaya Therapeutics
TNYA
$163M
$13.4M 24.12%
9,400,290
– –
SRZN icon
3
Surrozen
SRZN
$282M
$11.6M 20.85%
810,088
– –
RAPT
4
DELISTED
RAPT Therapeutics
RAPT
$2.1M 3.77%
166,077
-169,001
-50% -$2.15M
RVMD icon
5
Revolution Medicines
RVMD
$43.7B
$2.09K ﹤0.01%
46
– –
SGMT icon
6
Sagimet Biosciences
SGMT
$656M
– –
-17,169
Closed -$47.6K

Similar funds

PIS
POM Investment Strategies Raleigh, North Carolina $88.3M AUM 15.23% 1-Year Est. Return
FWM
FSR Wealth Management Elmhurst, Illinois $87.8M AUM 10.63% 1-Year Est. Return
WP
Walleye Partners Madison, Wisconsin $87.7M AUM
SHCM
Stone House Capital Management Bay Harbor Islands, Florida $88.5M AUM 149.16% 1-Year Est. Return
YIM
Yoffe Investment Management Lemoyne, Pennsylvania $87.4M AUM 30.8% 1-Year Est. Return
VPW
Variant Private Wealth Tysons, Virginia $88.9M AUM 25.07% 1-Year Est. Return
LC
Luminist Capital Grand Rapids, Michigan $89M AUM 17.66% 1-Year Est. Return
BI
Bradyco Inc Cambridge, Massachusetts $87.2M AUM 8.85% 1-Year Est. Return

Column Group's Q4 2024 Portfolio in Review

As of Q4 2024, Column Group held 6 positions worth $55.7M, down 20% from $69.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Column Group withdrew a net $2.19M in Q4 2024, closing 1 position and reducing 1 holding. Its most notable exit was Sagimet Biosciences, an estimated $47.6K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Column Group's biggest Q4 2024 reduction was RAPT Therapeutics, cutting an estimated $2.15M.
  • Column Group fully exited Sagimet Biosciences in Q4 2024, selling an estimated $47.6K.
  • Column Group's ten largest holdings make up 100% of its $55.7M portfolio in Q4 2024.
  • Column Group opened 0 new positions and closed 1 in Q4 2024.
  • Column Group's portfolio value fell 20% quarter-over-quarter to $55.7M.

Based on Column Group's 13F filing for Q4 2024, filed 14 Feb 2025.